Literature DB >> 17080242

Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.

Jinyu Gu1, Hirofumi Yamamoto, Hiroki Fukunaga, Katsuki Danno, Ichiro Takemasa, Masataka Ikeda, Mitsuaki Tatsumi, Mitsugu Sekimoto, Jun Hatazawa, Tsunehiko Nishimura, Morito Monden.   

Abstract

We investigated the wide variability of 18F-2-fluoro-2-deoxy-D: -glucose (FDG) uptake, semiquantified as standardized uptake value (SUV), in positron emission tomography (PET) scanning, in 20 patients with colorectal cancer (CRC), including 1 with synchronous hepatic metastasis. The sensitivity of PET in CRC diagnosis was 100%, with a mean SUV of 8.0 (3.1-11.9). Tumor size and depth of invasion were associated with higher SUVs (P=.0004, .042, respectively). Strong glucose transporter-1 (GLUT-1) expression had significantly positive correlation with the SUV (r=.619, P=.003). GLUT-1 expression revealed positive staining in 17 (85%) of the 20 primary lesions. The central part of the tumor, thought to be relatively hypoxic, had stronger GLUT-1 expression and a higher SUV than the periphery, in both the primary tumor and hepatic metastatic foci. Our data suggest that the SUVs of FDG uptake in PET may be a noninvasive biomarker for advanced CRC, indicative of a large hypoxic tumor with deep invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080242     DOI: 10.1007/s10620-006-9428-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features.

Authors:  K L Berger; S A Nicholson; F Dehdashti; B A Siegel
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

2.  Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.

Authors:  M H Whiteford; H M Whiteford; L F Yee; O A Ogunbiyi; F Dehdashti; B A Siegel; E H Birnbaum; J W Fleshman; I J Kodner; T E Read
Journal:  Dis Colon Rectum       Date:  2000-06       Impact factor: 4.585

3.  Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer.

Authors:  Hiroki Fukunaga; Mitsugu Sekimoto; Masataka Ikeda; Ichiro Higuchi; Masayoshi Yasui; Iwao Seshimo; Osamu Takayama; Hirofumi Yamamoto; Masayuki Ohue; Mitsuaki Tatsumi; Jun Hatazawa; Masakazu Ikenaga; Tsunehiko Nishimura; Morito Monden
Journal:  Ann Surg Oncol       Date:  2005-05-09       Impact factor: 5.344

4.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

5.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

6.  18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.

Authors:  Tzu-Chen Yen; Lai-Chu See; Chyong-Huey Lai; Chou Wu Yah-Huei; Koon-Kwan Ng; Shih-Ya Ma; Wuu-Jyh Lin; Jenn-Tzong Chen; Wen-Jie Chen; Chiung-Ru Lai; Swei Hsueh
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

7.  Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma.

Authors:  Hirofumi Koga; Yoshio Matsuo; Masayuki Sasaki; Makoto Nakagawa; Koichiro Kaneko; Kazutaka Hayashi; Yasuo Kuwabara; Hiroshi Honda
Journal:  Ann Nucl Med       Date:  2003-06       Impact factor: 2.668

8.  Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer.

Authors:  A K Paul; M Tatsumi; I Higuchi; H Fukunaga; T Yasuda; T Nishimura
Journal:  Nucl Med Commun       Date:  2003-09       Impact factor: 1.690

9.  Clinical and pathological prognostic indicators with colorectal mucinous carcinomas.

Authors:  Keisuke Kubota; Takayuki Akasu; Shin Fujita; Ken-ichi Sugihara; Yoshihiro Moriya; Seiichiro Yamamoto
Journal:  Hepatogastroenterology       Date:  2004 Jan-Feb

10.  Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.

Authors:  Hiroyuki Kato; Junko Takita; Tatsuya Miyazaki; Masanobu Nakajima; Yasuyuki Fukai; Norihiro Masuda; Minoru Fukuchi; Ryokuhei Manda; Hitoshi Ojima; Katsuhiko Tsukada; Hiroyuki Kuwano; Noboru Oriuchi; Keigo Endo
Journal:  Anticancer Res       Date:  2003 Jul-Aug       Impact factor: 2.480

View more
  28 in total

1.  Application of (18)F-fluorodeoxyglucose positron emission tomography to detection of proximal lesions of obstructive colorectal cancer.

Authors:  Shusuke Mori; Kazuhiro Oguchi
Journal:  Jpn J Radiol       Date:  2010-10-24       Impact factor: 2.374

2.  Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Megumi Jinguji; Nobuaki Nishimata; Shunji Shimaoka; Tohru Nihara; Kuniaki Aridome; Sadao Tanaka; Yoshihiko Fukukura; Atushi Tani; Chihaya Koriyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

3.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

4.  Prognostic value of 18F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer.

Authors:  Byung Hyun Byun; Sun Mi Moon; Ui Sup Shin; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

5.  Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Kunihiko Izuishi; Yuka Yamamoto; Takanori Sano; Ryusuke Takebayashi; Yoshihiro Nishiyama; Hirohito Mori; Tsutomu Masaki; Asahiro Morishita; Yasuyuki Suzuki
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

6.  An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Authors:  Heather Keen; Bernd Pichler; Damaris Kukuk; Olivier Duchamp; Olivier Raguin; Aoife Shannon; Nichola Whalley; Vivien Jacobs; Juliana Bales; Neill Gingles; Sally-Ann Ricketts; Stephen R Wedge
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

7.  Prognostic Significance of Volume-based Metabolic Parameters by (18)F-FDG PET/CT in Gallbladder Carcinoma.

Authors:  Jang Yoo; Joon Young Choi; Kyu Taek Lee; Jin Seok Heo; Soo Bin Park; Seung Hwan Moon; Yearn Seong Choe; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-19

8.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma.

Authors:  Xiao-Hong Wu; Su-Ping Chen; Jian-Ying Mao; Xue-Xian Ji; Hong-Tian Yao; Shui-Hong Zhou
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

Review 9.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

10.  Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer.

Authors:  Jang Eun Lee; Sang Woo Kim; Jin Su Kim; Kyu Yong Choi; Won Kyung Kang; Seong Taek Oh; Ie Ryung Yoo; Sung Hoon Kim
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.